![]()
|
|
||||||||
J. Biol. Chem., Vol. 275, Issue 24, 17917-17920, June 16, 2000
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Department of Neuropathology, Faculty of Medicine, University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo 113-0033, Japan and Core Research and Evolutional Science and Technology (CREST), Japan Science and Technology Corporation (JST), Kawaguchi 332-0012, Japan
Received for publication, March 17, 2000, and in revised form, April 12, 2000
| |
ABSTRACT |
|---|
|
|
|---|
Collapsin response mediator protein-2 (CRMP-2) is
a member of the CRMP/TOAD/Ulip/DRP family of cytosolic phosphoproteins
involved in neuronal differentiation and axonal guidance. CRMP-2
mediates the intracellular response to collapsin 1/semaphorin 3A, a
repulsive extracellular guidance cue for axonal outgrowth. The mutation of UNC-33, a Caenorhabditis elegans homolog of
CRMP-2, results in abnormality of microtubules in neurites, but the
mechanism of CRMP-2 action remains to be clarified. Here, we report
that overexpression of human CRMP-2 in Neuro2a cells, a mouse
neuroblastoma cell line, results in blebbing of the cytoplasm.
Furthermore, some cells exhibited intranuclear inclusions, which were
labeled with antibodies to CRMP-2 and tubulin. CRMP-2 was found to be associated with microtubule bundles in the spindles at the metaphase and in the midbodies at the late telophase in mitotic cells. Thus, it
is most likely that failure of complete disassembly of the spindle
microtubules during mitosis is responsible for the formation of these
intranuclear inclusions. We suggest that CRMP-2 functions by regulating
the dynamics of microtubules.
The development of the nervous system requires the growth of
neuritic processes and their guidance toward the appropriate targets
with which they must establish accurate synaptic contacts. Collapsin
response mediator proteins
(CRMPs)1 are a family of
cytosolic phosphoproteins involved in neurite outgrowth and axonal
guidance (1). Their expression and phosphorylation are spatially and
temporally regulated during development (2-4). Immunocytochemical
studies showed that CRMPs are distributed in the lamellipodia and
filopodia of the growth cone, the shaft of axons, and the neuronal cell
body (2, 3, 5).
CRMP-2 (also referred to as TOAD-64, Turned on
after Division, 64 kDa (2); Ulip2, or
UNC-33-like
phosphoprotein-2 (3); DRP-2,
dihydropyrimidinase-related
protein-2 (6)) is the member most widely
expressed within the nervous system. The protein has been reported to
mediate semaphorin III/D-induced growth cone collapse through a signal
transduction cascade involving G-protein (5).
CRMP-2 has a sequence homologous to the product of unc-33, a
nematode gene required for appropriately directed axonal extension (7).
Mutations of unc-33 result in abnormal outgrowth of axons, leading to severely uncoordinated movements in Caenorhabditis elegans (8). Neurites in the mutant showed significant defects in
microtubule organization; a superabundance of microtubules was found in
sensory dendrites, and some of these microtubules were larger than
normal in diameter, and some formed hooks or multiple tubules. These
findings suggest that the axonal guidance defects are a
consequence of cytoskeletal, in particular, microtubular, abnormalities and that the product of unc-33 should be
involved in appropriate organization of microtubules in neurites. A
straightforward interpretation is that UNC-33 is a
microtubule-associated protein that should control the assembly or
stability of microtubules in vivo. However, no distinct
cytoskeletal association of CRMP-2 has thus far been recognized.
CRMP-2 may also be involved in the process of neurodegeneration. Highly
phosphorylated forms of CRMP-2 were shown to be associated with
neurofibrillary tangles in Alzheimer's disease brains (9, 10).
Semaphorin III/D and CRMP-2 have also been reported to mediate neuronal
death in a dopamine-induced apoptotic cell model (11).
To study the functions of CRMP-2, especially its possible effects on
the cytoskeleton, we established a regulable expression system for
hCRMP-2 in Neuro2a (N2a) cells, a mouse neuroblastoma cell line, using
the ecdysone-inducible mammalian expression system. In this system, the
extent of CRMP-2 expression can be regulated by varying the dose of the
inducer, ponasterone A. The potential toxic effects of overproduced
CRMP-2 may thus be avoided, and changes attributable to CRMP-2 itself
may be assessed more accurately. Here, we show evidence suggesting that
CRMP-2 affects microtubule dynamics: overexpression of hCRMP-2 in N2a
cells induced blebbing of the cytoplasm (and subsequent apoptosis of
the cells); acetylated tubulin and CRMP-2 were occasionally deposited
as intranuclear inclusions; and CRMP-2 was associated with microtubule
bundles in the spindles at the metaphase and in the midbodies at the
late telophase in mitotic cells.
Generation of Stable N2a Cell Lines with Inducible CRMP-2
Expression--
A pTARGET-hCRMP-2 construct expressing hCRMP-2 was
prepared by polymerase chain reaction as described before (10). The
cDNA fragment encoding the complete sequence for hCRMP-2 was then
cut with EcoRI and NotI from the plasmid and
inserted into the pIND(SP1) vector. The new construct was named
pIND(SP1)-hCRMP-2.
A founder N2a cell line stably transfected with pVgRXR
(Zeocin-resistant), which constitutively expresses a functional
ecdysone receptor, was established as described (12). The founder cells were then transfected with pIND(SP1)-hCRMP-2 to generate double-stable transfectants expressing hCRMP-2. Pooled clones were established by
selection using 0.4 mg/ml Zeocin and 1.0 mg/ml G418. Monoclones were
then screened for CRMP-2 expression in response to ponasterone A by
Western blot analysis and immunofluorescence observation using C4G, a
monoclonal antibody to CRMP-2 (10). Clones with the highest expression
and tightest regulation were selected for further study. The multiple
independent expression lines obtained yielded similar experimental
results. For the negative control, the founder N2a cell line with the
vector pIND(SP1) was mock-transfected. Stable cell lines were cultured
in Dulbecco's modified Eagle's medium (Life Technologies, Inc.)
containing 10% fetal bovine serum, 0.4 mg/ml Zeocin, and 0.4 mg/ml G418.
Western Blot Analysis--
Cells were cultured in 6-well plates
and treated with ponasterone A as indicated. They were then rinsed once
with phosphate-buffered saline (PBS) and solubilized on ice with a
lysis buffer containing 50 mM sodium phosphate (pH 7.4),
150 mM NaCl, 0.5% Triton X-100, 1 mM EDTA, and
a mixture of protease inhibitors (0.5 mM
phenylmethylsulfonyl fluoride, 1 µg/ml
N Measurements of Cell Viability--
Cell viability was
determined by MTT assay or trypan blue exclusion assay as described
(12). For the MTT assay, aliquots (150 µl) of the cell suspension
(6 × 104 cells/ml) were subcultured in the wells of a
96-well plate. For the neuron-like phenotype, cells were differentiated
with 5 mM Bt2cAMP (Sigma) and CRMP-2 expression
was induced with ponasterone A. After 3 days, 50 µl of MTT (2 mg/ml
in PBS) was added to each well, and the plate was further incubated for
2 h. The reaction was then stopped by replacing 100 µl of the
culture medium with an equal volume of 0.05 N HCl in
isopropanol, and the cells were disrupted by pipetting. The cell
viability was determined colorimetrically using an automated 96-well
plate reader (Molecular Devices, Sunnyvale, CA) and the SOFTmax
software to measure the absorbance at 570-650 nm. 100% cell killing
was set as that caused by the addition of Triton X-100 at a final
concentration of 0.5% 30 min prior to the addition of MTT.
For the trypan blue exclusion assay, aliquots (1 ml) of the cell
suspension (7.5 × 104 cells/ml) were added to the
wells of a 24-well plate (Falcon) and treated with 5 mM
Bt2cAMP and 5 µM ponasterone A, and the cells
were counted every day after trypan blue staining. At least 200 cells
were scored for each experiment.
Immunocytochemistry--
For immunofluorescence microscopy, the
cells were plated onto 15-mm round coverslips in a 12-well plate
(2 × 104 cells in 1 ml of medium) and treated with
ponasterone A for the indicated periods. After a brief rinse in PBS,
the cells were fixed with 4% paraformaldehyde in PBS at room
temperature for 20 min, permeabilized with 0.3% Triton X-100 in PBS
for 5 min, blocked with 10% calf serum in PBS for 30 min, and then
incubated overnight with each primary antibody. The primary antibodies
used in this study were: N356, a mouse monoclonal antibody to
Nuclei were visualized by staining with 5 µg/ml Hoechst 33258 for 20 min after second antibody binding. Rhodamine-phalloidin (R-415,
Molecular Probes, Inc.) was used at this step for F-actin labeling when necessary.
Specimens were examined under either a Zeiss Axioskop microscope (Carl
Zeiss Co., Tokyo) or an attached Bio-Rad laser scanning confocal
imaging system (Microradiance R2000/AG-2) equipped with the
Lasersharp2000 software (Bio-Rad). Images were processed using the
Lasersharp2000 post-processing software and Adobe Photoshop (Adobe Systems).
Inducible Expression of CRMP-2 in N2a Cells--
To study the
biological functions of CRMP-2 in the cell, we employed an
ecdysone-inducible system to obtain regulable expression of hCRMP-2 in
N2a cells. To assess inducible CRMP-2 expression, the lysate of a
representative clone was analyzed by Western blotting. As shown in Fig.
1, expression of CRMP-2 was induced by
ponasterone A in a dose-dependent manner. Very low levels
of CRMP-2 were found to be expressed in N2a cells in the absence of
ponasterone A. This level of expression was the same as that in
nontransfected cells and was thus considered representative of the
level of endogenous CRMP-2. With increasing dose of ponasterone A, the
expression levels of CRMP-2 increased, but with >1 µM
ponasterone A the expression became saturated at a level that was about
7-fold that of the endogenous level. In the case of tau, a
microtubule-associated protein, no saturation of inducible expression
was observed up to 5 µM ponasterone A (data not shown),
probably because high levels of CRMP-2 are toxic to the cell; the cells
expressing higher levels of CRMP-2 started to die (see below).
Overexpression of CRMP-2 Results in Blebbing of the Cytoplasm and
Subsequent Death of N2a Cells--
The effects of CRMP-2
overexpression in N2a cells were first examined under a phase-contrast
microscope. After 10-12 h of induction with 5 µM
ponasterone A, some cells became rounded and detached from the tissue
culture plate. Blebbing of the cytoplasm could be observed in some
cells at this stage, and cell death occurred after prolonged induction
with ponasterone A. About 15% of the cells died after 24 h of
induction with 5 µM ponasterone A, as judged by trypan
blue staining.
Immunostaining using antibodies to CRMP-2 showed that blebbing of the
cytoplasm appeared only in those cells that expressed higher levels of
CRMP-2 (Fig. 2A). The levels
of inducibly expressed CRMP-2 varied even among the cells of a
monoclonal origin, and its levels in the dying cells were well above
those in the morphologically normal ones. If the mean level of CRMP-2
induced by 2 µM ponasterone A is assumed to be about
7-fold that of the endogenous levels, much higher levels must have been
expressed in the dying cells. Most of the cells showing cytoplasmic
blebbing had intact nuclei, suggesting that alteration of the
cytoskeleton occurred before the condensation of nuclei (Fig.
2B).
Cell death was demonstrated by MTT assay and trypan blue exclusion. The
cell viability decreased depending on the dose of ponasterone A,
becoming significant with >2 µM ponasterone A (Fig. 2C). Although differentiated N2a cells were used in these
studies, in our hands, only about 80% of the cells were differentiated by treatment with 5 mM Bt2cAMP for 24 h,
as judged by generation of neurite-like processes. The remaining
undifferentiated cells still underwent division, and the cell numbers
increased significantly after 2 days (Fig. 2D). Trypan blue
staining showed no obvious effect of Bt2cAMP treatment on
survival of N2a cells, as reported by others (12). In contrast, the
fraction of cells that did not exclude trypan blue increased
significantly upon treatment with ponasterone A, reaching 50-60%
after 5 days of treatment. Thus, the decreased cell viability was
largely due to cell death, although inhibition of cell proliferation by
CRMP-2 might also contribute to some extent. There was no significant
change in the viability of mock-transfected cells by ponasterone A
treatment (data not shown).
Association of CRMP-2 with Microtubule Bundles--
The
distribution of CRMP-2 in N2a cells was examined by immunofluorescence
before and after induction by ponasterone A, using C4G, a monoclonal
antibody to CRMP-2. As reported by others, CRMP-2 was diffusely
distributed in the cytoplasm. This distribution was distinct from that
of microtubules, actin filaments (Fig. 3A), or neurofilaments (data
not shown) in N2a cells. However, in some N2a cells overexpressing
CRMP-2, the monoclonal antibody also labeled some distinct structures,
i.e. the spindles at the metaphase and the midbodies at the
late telophase in mitotic cells. These structures are characterized by
the presence of microtubule bundles. Colocalization was confirmed by
double labeling with the antibodies to Intranuclear Inclusions of CRMP-2 and Tubulin in N2a Cells--
We
found that intranuclear inclusions were formed in a small proportion of
N2a cells (~2%) overexpressing CRMP-2. In such cells, stronger
immunostaining of CRMP-2 was found in the inclusions than in the
cytoplasm. These inclusions had a regular outline, and most appeared
globular and were 1-2 µm in diameter (Fig.
4A). An antibody to
An antibody to acetylated-tubulin weakly stained the microtubules in
the cytoplasm. However, it strongly labeled the intranuclear inclusions, suggesting that the deposits are composed mainly of the
mature form of tubulin (Fig. 4C).
The CRMP/TOAD/Ulip/DRP family of cytosolic proteins play important
roles in neuronal differentiation and axonal guidance. The lack of
sequence homology between the CRMP/UNC-33 family and other proteins in
data bases indicates that CRMPs may have a unique and as yet poorly
understood molecular mechanism of action.
Our results point to the involvement of CRMP-2 in the regulation of
microtubule dynamics. First, CRMP-2 was associated with bundled
microtubules in N2a cells. In this respect, CRMP-2 differs from
classical microtubule-associated proteins, which are associated with
individual microtubules. In vitro assembly/disassembly
cycles of microtubules revealed no direct association of CRMP-2 (data not shown). CRMP-2 may be involved in the interaction between microtubules or may help link the microtubules to other cellular components. All members of the CRMP family have a basic region, adjacent to a differentially phosphorylated region, in the
carboxyl-terminal portion of the molecule (10). The basic region may be
responsible for direct or indirect binding to the microtubules, which
is likely regulated by phosphorylation of the adjacent region. It has
been reported that CRMPs exist as (hetero)tetramers (13), a good candidate for a cross-linker of individual microtubules. Second, overexpression of CRMP-2 led to blebbing of the cytoplasm of N2a cells.
This event is believed to be due to cytoskeletal alterations affecting
the dynamics of actin or defective interactions between microfilaments
and microtubules. Finally, overexpression of CRMP-2 in N2a cells
induced deposition of tubulin, in particular, its stable form, as
intranuclear inclusions. Acetylation of CRMP-2 has been reported to be necessary for G-protein-mediated
transduction of an extracellular collapsin signal into growth cone
collapse (5). However, the observed G-protein-independent effects of
pertussis toxin on neurite growth and growth cone morphology (15)
suggest that CRMP might also be a component of a
non-G-protein-dependent signaling pathway. Alterations of
the cytoskeletal network have been proposed to be involved in changes
of the growth cone morphology in response to extracellular cues. The
actively extended tips of the growth cone are filled with a population
of dynamic actin filaments. Microtubules are found in abundance in the
central domain of the growth cone, with some of them extending to the base of the filopodia at the leading edge; they play important roles in
the maintenance and regulation of the growth cone remodeling by forming
highly stable cross-linked bundles (16, 17). In N2a cells, CRMP-2
partially overlaps with filamentous actin in the spreading cytoplasm
(see Fig. 3A). However, no apparent change of organization
of actin filaments was found in the cells overexpressing CRMP-2. We
suggest that one pathway of CRMP-2 mediated-collapsing activity is
through its regulation of microtubule reorganization. A cascade of
kinase activities may be involved in the collapsin signaling pathway,
in which Rac1 regulates the organization of actin filaments (18), and
phosphorylation of CRMP-2 may destabilize microtubule bundles in the
growth cone. On the other hand, the stabilizing effect of CRMP-2 on the
specific microtubule arrangements in the axon shaft contributes to its
maintenance. In support of this assumption, the phosphorylation level
of CRMP-2 in the brain under development is much greater than that of
inducibly expressed CRMP-2 in N2a cells (9, 10).
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-p-tosyl-L-lysine
chloromethyl ketone, 1 µg/ml leupeptin, 1 µg/ml pepstatin, and
1 µg/ml antipain). The lysates were centrifuged at 10,000 × g for 15 min, and the supernatants were saved. The protein
concentration in each sample was determined by bicinchoninic acid
protein assay (Pierce), and equal amounts of protein (2.5 µg/lane)
were subjected to 10% SDS-polyacrylamide gel electrophoresis followed
by Western blotting using a mixture of monoclonal antibodies to CRMP-2
(C4G and N3E) as described previously (10). The relative expression
levels of CRMP-2 were quantitated using a GS700 Imaging Densitometer
(Bio-Rad).
-tubulin (Amersham Pharmacia Biotech); a mouse monoclonal antibody
to acetylated tubulin (clone 6-11B-1, Sigma); mouse monoclonal
antibodies to CRMP-2, C4G, and N3E; and a rabbit polyclonal antibody to
CRMP-2, A667 (10). As the secondary antibodies, FITC-conjugated goat anti-mouse IgG or rhodamine-conjugated donkey anti-rabbit IgG (Jackson
ImmunoResearch Laboratory, West Grove, PA) was used.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (34K):
[in a new window]
Fig. 1.
Inducible expression of CRMP-2 in N2a
cells. A cell line stably transfected with hCRMP-2 was induced
with 0, 0.2, 0.5, 1.0, 2.0, or 5.0 µM ponasterone A for
24 h, lyzed with 0.5% Triton X-100, and subjected to Western blot
analysis as described under "Experimental Procedures." The
upper panel shows a representative Western blot of hCRMP-2
detected with a mixture of monoclonal antibodies to CRMP-2, C4G, and
N3E. Aliquots of lysate containing the same amount of protein (2.5 µg) were loaded on each lane. The lower panel represents
quantitation of the Western blots by densitometry, with the levels
expressed relative to those in noninduced cells (means ± S.D.
from four independent experiments).

View larger version (26K):
[in a new window]
Fig. 2.
Overexpression of CRMP-2 caused blebbing of
the cytoplasm and cell death. A and B,
pooled clones of N2a cells expressing hCRMP-2 were treated with 2 µM ponasterone A for 24 h and immunolabeled with
C4G, a monoclonal antibody to CRMP-2, followed by incubation with
FITC-conjugated goat anti-mouse IgG (A). The nuclei were
visualized with Hoechst 33258 (B) as described under
"Experimental Procedures." The arrow in each panel
indicates a cell expressing high levels of CRMP-2 and blebbing without
any obvious changes in the nucleus. C, cell differentiation
was induced with 5 mM Bt2cAMP and CRMP-2
expression with 0, 1.0, 2.0, or 5.0 µM ponasterone A for
3 days. The viability of the cells on day 3 was determined using an MTT
assay. The data are the means ± S.D. (bars) from 16 cultures. The viability of the cells not subjected to ponasterone A
treatment (0 µM) was regarded as 100%. D,
cell differentiation was induced with 5 mM
Bt2cAMP and CRMP-2 expression with 5.0 µM
ponasterone A, and the cell numbers were counted every 24 h
following trypan blue staining. The data are the mean ± S.D.
(bars) from four independent cultures. Statistics were
performed by one-way analysis of variance followed by Bonferroni's
multiple comparison test (C) and Student's t
test (D). Values significantly different from nontreated
cells are labeled as follows: *, p < 0.01; **,
p < 0.0001.
-tubulin and CRMP-2 (Fig.
3B).

View larger version (41K):
[in a new window]
Fig. 3.
Distribution of CRMP-2 and cytoskeleton in
N2a cells. A, cells were induced with 2 µM ponasterone A for 24 h, immunostained with a
monoclonal antibody to
-tubulin (left), or double-stained
with rhodamine-conjugated phalloidin (middle) and a
monoclonal antibody to CRMP-2, C4G (right). B,
colocalization of CRMP-2 with microtubule bundles in the spindle at the
metaphase (upper panel) and in the midbody at the late
telophase (lower panel) in mitotic cells. Double labeling
was performed with a monoclonal antibody to
-tubulin and a
polyclonal antibody to CRMP-2, A667; the primary antibodies were
detected with FITC-conjugated goat anti-mouse IgG (green) or
rhodamine-conjugated donkey anti-rabbit IgG (red),
respectively. Micrographs were obtained under a laser scanning confocal
microscope. For B, a series of optical sections through the
cell was collected and projected onto a single-image plane. The
superimposed images are presented on the right. Yellow
indicates colocalization of CRMP-2 with
-tubulin.
-tubulin strongly stained these intranuclear inclusions (Fig.
4B). The inclusions were quite compact and replaced the chromatin, as seen in Hoechst dye-negative areas in the nucleus (Fig.
4C). No correlation was observed between the formation of intranuclear inclusion and the blebbing of cytoplasm or the
condensation of chromatin. Sometimes the inclusions appeared as tapered
to curly thick fibers continuous with the cytoplasmic microtubules (Fig. 4B), suggesting that they originate from the
microtubule bundles formed during mitosis. This view was further
supported by an observation that very few inclusions appeared in the
N2a cells differentiated by Bt2cAMP.

View larger version (33K):
[in a new window]
Fig. 4.
Intranuclear inclusions in N2a cells
overexpressing CRMP-2. Cells were treated with 1 µM
ponasterone A for 72 h. After fixation with 4% formaldehyde, the
cells were labeled with a monoclonal antibody to CRMP-2 (A)
or a monoclonal antibody to
-tubulin (B) followed by FITC
labeling; they were then observed with a confocal microscope.
C, double staining with a monoclonal antibody to acetylated
tubulin (green) and a polyclonal antibody to CRMP-2, A667
(red), was performed as described in the legend for Fig. 3.
The nuclei were visualized by Hoechst 33258 staining, and the
photomicrograph of the same field was obtained under a Zeiss Axioskop
microscope with a 63× objective. The arrows indicate two
intranuclear inclusions.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-tubulin is a relatively
slow enzymatic reaction that occurs only on microtubules and not on
free tubulin molecules. The reaction is rapidly reversed when tubulin
molecule depolymerizes (14). Thus, the presence in abundance of
acetylated tubulin in the intranuclear inclusions indicates that they
originate from stable microtubules. The stabilizing effect of
overexpressed CRMP-2 on bundles of microtubule structures likely
results in the failure of disassembly of spindles during cell division.
The present finding may thus explain, in part, some observations in the
unc-33 mutant of C. elegans, in which the
neurites contain a great abundance of microtubules (8).
| |
ACKNOWLEDGEMENTS |
|---|
We thank Dr. T. Yamazaki for help with the immunocytochemical analysis, Drs. G. Wang and N. Nukina for providing the founder N2a cells, and M. Anzai for typing the manuscript.
| |
FOOTNOTES |
|---|
* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of
Neuropathology, Faculty of Medicine, University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo 113-0033, Japan. Tel.: 81-3-5841-3541; Fax:
81-3-5800-6852; E-mail: yihara@m.u-tokyo.ac.jp.
Published, JBC Papers in Press, April 17, 2000, DOI 10.1074/jbc.C000179200
| |
ABBREVIATIONS |
|---|
The abbreviations used are: CRMP, collapsin response mediator protein; hCRMP-2, human CRMP-2; PBS, phosphate-buffered saline; Bt2cAMP, N6,2'-O-dibutyryladenosine-3':5'-cyclic monophosphate; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; FITC, fluorescein isothiocyanate; N2a cells, Neuro2a cells.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Quinn, C. C., Gray, G. E., and Hockfield, S. (1999) J. Neurobiol. 41, 158-164 |
| 2. | Minturn, J. E., Fryer, H. J., Geschwind, D. H., and Hockfield, S. (1995) J. Neurosci. 15, 6757-6766 |
| 3. | Byk, T., Dobransky, T., Cifuentes-Diaz, C., and Sobel, A. (1996) J. Neurosci. 16, 688-701 |
| 4. | Wang, L. H., and Strittmatter, S. M. (1996) J. Neurosci. 16, 6197-6207 |
| 5. | Goshima, Y., Nakamura, F., Strittmatter, P., and Strittmatter, S. M. (1995) Nature 376, 509-514 |
| 6. | Hamajima, N., Matsuda, K., Sakata, S., Tamaki, N., Sasaki, M., and Nonaka, M. (1996) Gene 180, 157-163 |
| 7. | Li, W., Herman, R. K., and Shaw, J. E. (1992) Genetics 132, 675-689 |
| 8. | Hedgecock, E. M., Culotti, J. G., Thomson, J. N., and Perkins, L. A. (1985) Dev. Biol. 111, 158-170 |
| 9. | Yoshida, H., Watanabe, A., and Ihara, Y. (1998) J. Biol. Chem. 273, 9761-9768 |
| 10. | Gu, Y., Hamajima, N., and Ihara, Y. (2000) Biochemistry 39, 4267-4275 |
| 11. | Shirvan, A., Ziv, I., Fleminger, G., Shina, R., He, Z., Brudo, I., Melamed, E., and Barzilai, A. (1999) J. Neurochem. 73, 961-971 |
| 12. | Wang, G. H., Mitsui, K., Kotliarova, S., Yamashita, A., Nagao, Y., Tokuhiro, S., Iwatsubo, T., Kanazawa, I., and Nukina, N. (1999) Neuroreport 10, 2435-2438 |
| 13. | Wang, L. H., and Strittmatter, S. M. (1997) J. Neurochem. 69, 2261-2269 |
| 14. | Greer, K., and Rosenbaum, J. L. (1989) in Kinesin, Dynein, and Microtubule Dynamics (Warner, F. D. , and McIntosh, J. R., eds), Vol. 2 , pp. 47-66, Wiley-Liss, New York |
| 15. | Kindt, R. M., and Lander, A. D. (1995) Neuron 15, 79-88 |
| 16. | Tanaka, E., and Kirschner, M. (1991) J. Cell Biol. 115, 345-363 |
| 17. | Challacombe, J. F., Snow, D. M., and Letourneau, P. C. (1997) J. Neurosci. 17, 3085-3095 |
| 18. | Jin, Z., and Strittmatter, S. M. (1997) J. Neurosci. 17, 6256-6263 |
This article has been cited by other articles:
![]() |
K.-Y. Su, W.-L. Chien, W.-M. Fu, I-S. Yu, H.-P. Huang, P.-H. Huang, S.-R. Lin, J.-Y. Shih, Y.-L. Lin, Y.-P. Hsueh, et al. Mice Deficient in Collapsin Response Mediator Protein-1 Exhibit Impaired Long-Term Potentiation and Impaired Spatial Learning and Memory J. Neurosci., March 7, 2007; 27(10): 2513 - 2524. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Charrier, B. Mosinger, C. Meissirel, M. Aguera, V. Rogemond, S. Reibel, P. Salin, N. Chounlamountri, V. Perrot, M.-F. Belin, et al. Transient alterations in granule cell proliferation, apoptosis and migration in postnatal developing cerebellum of CRMP1-/- mice Genes Cells, December 1, 2006; 11(12): 1337 - 1352. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. T. Hou, S. X. Jiang, A. Desbois, D. Huang, J. Kelly, L. Tessier, L. Karchewski, and J. Kappler Calpain-cleaved collapsin response mediator protein-3 induces neuronal death after glutamate toxicity and cerebral ischemia. J. Neurosci., February 22, 2006; 26(8): 2241 - 2249. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Vincent, Y. Collette, R. Marignier, C. Vuaillat, V. Rogemond, N. Davoust, C. Malcus, S. Cavagna, A. Gessain, I. Machuca-Gayet, et al. A Role for the Neuronal Protein Collapsin Response Mediator Protein 2 in T Lymphocyte Polarization and Migration J. Immunol., December 1, 2005; 175(11): 7650 - 7660. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Arimura, C. Menager, Y. Kawano, T. Yoshimura, S. Kawabata, A. Hattori, Y. Fukata, M. Amano, Y. Goshima, M. Inagaki, et al. Phosphorylation by Rho Kinase Regulates CRMP-2 Activity in Growth Cones Mol. Cell. Biol., November 15, 2005; 25(22): 9973 - 9984. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-H. Lin, S. Hansen, Z. Wang, D. R. Storm, S. J. Tapscott, and J. M. Olson The dosage of the neuroD2 transcription factor regulates amygdala development and emotional learning PNAS, October 11, 2005; 102(41): 14877 - 14882. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Kashiwagi, M. Shiraga, H. Kato, T. Kamae, N. Yamamoto, S. Tadokoro, Y. Kurata, Y. Tomiyama, and Y. Kanakura Negative regulation of platelet function by a secreted cell repulsive protein, semaphorin 3A Blood, August 1, 2005; 106(3): 913 - 921. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Uchida, T. Ohshima, Y. Sasaki, H. Suzuki, S. Yanai, N. Yamashita, F. Nakamura, K. Takei, Y. Ihara, K. Mikoshiba, et al. Semaphorin3A signalling is mediated via sequential Cdk5 and GSK3{beta} phosphorylation of CRMP2: implication of common phosphorylating mechanism underlying axon guidance and Alzheimer's disease Genes Cells, February 1, 2005; 10(2): 165 - 179. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Brown, T. Jacobs, B. Eickholt, G. Ferrari, M. Teo, C. Monfries, R. Z. Qi, T. Leung, L. Lim, and C. Hall {alpha}2-Chimaerin, Cyclin-Dependent Kinase 5/p35, and Its Target Collapsin Response Mediator Protein-2 Are Essential Components in Semaphorin 3A-Induced Growth-Cone Collapse J. Neurosci., October 13, 2004; 24(41): 8994 - 9004. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. K. Hussain, M. Yamabhai, A. L. Bhakar, M. Metzler, S. S. G. Ferguson, M. R. Hayden, P. S. McPherson, and B. K. Kay A Role for Epsin N-terminal Homology/AP180 N-terminal Homology (ENTH/ANTH) Domains in Tubulin Binding J. Biol. Chem., August 1, 2003; 278(31): 28823 - 28830. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. C. Quinn, E. Chen, T. G. Kinjo, G. Kelly, A. W. Bell, R. C. Elliott, P. S. McPherson, and S. Hockfield TUC-4b, a Novel TUC Family Variant, Regulates Neurite Outgrowth and Associates with Vesicles in the Growth Cone J. Neurosci., April 1, 2003; 23(7): 2815 - 2823. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Franken, U. Junghans, V. Rosslenbroich, S. L. Baader, R. Hoffmann, V. Gieselmann, C. Viebahn, and J. Kappler Collapsin Response Mediator Proteins of Neonatal Rat Brain Interact with Chondroitin Sulfate J. Biol. Chem., January 24, 2003; 278(5): 3241 - 3250. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Mikule, J. C. Gatlin, B. A. de la Houssaye, and K. H. Pfenninger Growth Cone Collapse Induced by Semaphorin 3A Requires 12/15-Lipoxygenase J. Neurosci., June 15, 2002; 22(12): 4932 - 4941. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Benvenuti, R. Cramer, C. C. Quinn, J. Bruce, M. Zvelebil, S. Corless, J. Bond, A. Yang, S. Hockfield, A. L. Burlingame, et al. Differential Proteome Analysis of Replicative Senescence in Rat Embryo Fibroblasts Mol. Cell. Proteomics, April 1, 2002; 1(4): 280 - 292. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-Y. Shih, S.-C. Yang, T.-M. Hong, A. Yuan, J. J. W. Chen, C.-J. Yu, Y.-L. Chang, Y.-C. Lee, K. Peck, C.-W. Wu, et al. Collapsin Response Mediator Protein-1 and the Invasion and Metastasis of Cancer Cells J Natl Cancer Inst, September 19, 2001; 93(18): 1392 - 1400. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Ricard, V. Rogemond, E. Charrier, M. Aguera, D. Bagnard, M.-F. Belin, N. Thomasset, and J. Honnorat Isolation and Expression Pattern of Human Unc-33-Like Phosphoprotein 6/Collapsin Response Mediator Protein 5 (Ulip6/CRMP5): Coexistence with Ulip2/CRMP2 in Sema3A- Sensitive Oligodendrocytes J. Neurosci., September 15, 2001; 21(18): 7203 - 7214. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |